NCT04848740

Brief Summary

Stroma is a fibrous, tough, transparent and the thickest layer of the corneae. The stroma is composed of organised collagen, which maintains transparency. Keratocytes are located between the lamella collagen fibers and secrete an extracellular matrix, which includes collagen, proteoglycan, crystalline proteins to maintain corneal transparency.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
9mo left

Started Feb 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Feb 2018Feb 2027

Study Start

First participant enrolled

February 1, 2018

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

April 14, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 19, 2021

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Expected
Last Updated

February 26, 2025

Status Verified

February 1, 2025

Enrollment Period

8 years

First QC Date

April 14, 2021

Last Update Submit

February 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Increase of corneal thickness

    Increase of corneal central thickness using human fresh corneal lenticule with stromal stem cells and live keratocytes

    24 months

Study Arms (1)

FRESH CORNEAL LENTICULE IMPLANTATION

OTHER

The aim in our study is to describe the importance of stroma as criteria of corneal thickness at implanting human fresh corneal lenticule in progressive corneal disease. We have conclude that every biomechanical instability of corneal stroma function(abnormal increase collagen activity,decrease proteinase inhibitors,excessive premature keratocyte apoptosis) describe the role of stroma in corneal thickness.

Device: ReLex-smile

Interventions

Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes

FRESH CORNEAL LENTICULE IMPLANTATION

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • progressive corneal disease with thin corneal thickness
  • corneal low transparenc
  • low visual acuity

You may not qualify if:

  • active anterior segment pathology
  • previous corneal or anterior segment surgery
  • other infection etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eye Hospital Pristina

Pristina, 10000, Kosovo

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Ophthalmology Department

Study Record Dates

First Submitted

April 14, 2021

First Posted

April 19, 2021

Study Start

February 1, 2018

Primary Completion

February 1, 2026

Study Completion (Estimated)

February 1, 2027

Last Updated

February 26, 2025

Record last verified: 2025-02

Locations